Your shopping cart is currently empty

EGFR Kinase Inhibitor 4 (Compound 4) acts as a bivalent ATP-allosteric inhibitor targeting EGFR, with a potent inhibitory effect (IC 50: 1.8 nM) on mutant EGFR (LRTMCS). It is primarily utilized in the study of non-small cell lung cancer (NSCLC) [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,420 | 3-6 months | 3-6 months | |
| 50 mg | $3,180 | 3-6 months | 3-6 months | |
| 100 mg | $4,300 | 3-6 months | 3-6 months |
| Description | EGFR Kinase Inhibitor 4 (Compound 4) acts as a bivalent ATP-allosteric inhibitor targeting EGFR, with a potent inhibitory effect (IC 50: 1.8 nM) on mutant EGFR (LRTMCS). It is primarily utilized in the study of non-small cell lung cancer (NSCLC) [1]. |
| In vitro | EGFR kinase inhibitor 4 (0-10 μM, 6 hours) reduces LRTM phosphorylation (pY1068) and downstream pERK and pAKT in human NSCLC cell lines (H1975, H3255, HCC827 cells) [1]. |
| Molecular Weight | 690.75 |
| Formula | C40H34N8O4 |
| Cas No. | 2922402-05-7 |
| Smiles | C(C)C=1NC(=C(N1)C2=CC(NC(=O)C3=C4C(NC=5C(C(=O)N4)=CC=CC5)=CC=C3)=CC=C2)C=6C=C(NC7=C(OC)C=CC(NC(C=C)=O)=C7)N=CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.